AR035475A1 - Forma b polimorfa del telmisartan, las mezclas de los polimorfos del telmisartan, un procedimiento para la preparacion del telmisartan que contiene la forma b polimorfa, y el uso del telmisartan para preparar un medicamento - Google Patents

Forma b polimorfa del telmisartan, las mezclas de los polimorfos del telmisartan, un procedimiento para la preparacion del telmisartan que contiene la forma b polimorfa, y el uso del telmisartan para preparar un medicamento

Info

Publication number
AR035475A1
AR035475A1 ARP000100241A ARP000100241A AR035475A1 AR 035475 A1 AR035475 A1 AR 035475A1 AR P000100241 A ARP000100241 A AR P000100241A AR P000100241 A ARP000100241 A AR P000100241A AR 035475 A1 AR035475 A1 AR 035475A1
Authority
AR
Argentina
Prior art keywords
telmisartan
polymorphin
polymorphic
mixtures
prepare
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP000100241A
Other languages
English (en)
Inventor
Schneider Heinrich Dr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR035475A1 publication Critical patent/AR035475A1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Forma B polimorfa del ácido 4'-[2-n-propil-4-metil-6-(1-metilbencimidazol-2-il)bencimidazol-1-ilmetil]-bifenil-2-carboxílico (INN: Telmisartán), de fórmula (1) que se caracteriza por un máximo endotérmico de 183 +/- 2°C que se manifiesta en el análisis térmico mediante CBD (calorimetría de barrido diferencial). Las mezclas de las formas polimorfas A - la cual ya era conocida en el estado del arte - y la forma polimorfa B que conforman el Telmisartán, y el uso de este último para prepara un medicamento. Un procedimiento para preparar Telmisartán, que contiene la forma polimorfa B, en el cual primero se obtiene únicamente la forma B con su forma cristalina macroscópica característica, la cual se conserva ampliamente en la forma polimorfa A que surge hacia el final del secado en virtud de una transformación parcial de la forma B bajo las condiciones dadas. El procedimiento consiste en: a) recoger el Telmisartán en una mezcla de disolventes compuesta por agua, ácido fórmico y un disolvente orgánico miscible con ello, calentar y, a continuación, filtrar la solución obtenida; b) separar el disolvente orgánico por destilación- eventualmente bajo incorporación por dosificación simultánea de agua -; c) precipitar la forma B del Telmisartán de la solución remanente mediante adición de una base; d) separar el producto precipitado por centrifugación, lavar y secar.
ARP000100241A 1999-01-19 2000-01-19 Forma b polimorfa del telmisartan, las mezclas de los polimorfos del telmisartan, un procedimiento para la preparacion del telmisartan que contiene la forma b polimorfa, y el uso del telmisartan para preparar un medicamento Pending AR035475A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19901921A DE19901921C2 (de) 1999-01-19 1999-01-19 Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels

Publications (1)

Publication Number Publication Date
AR035475A1 true AR035475A1 (es) 2004-06-02

Family

ID=7894715

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100241A Pending AR035475A1 (es) 1999-01-19 2000-01-19 Forma b polimorfa del telmisartan, las mezclas de los polimorfos del telmisartan, un procedimiento para la preparacion del telmisartan que contiene la forma b polimorfa, y el uso del telmisartan para preparar un medicamento

Country Status (36)

Country Link
EP (1) EP1144386B1 (es)
JP (1) JP4700813B2 (es)
KR (1) KR100658959B1 (es)
CN (1) CN1144790C (es)
AR (1) AR035475A1 (es)
AT (1) ATE252564T1 (es)
AU (1) AU765081B2 (es)
BG (1) BG65027B1 (es)
BR (1) BR0007584A (es)
CA (1) CA2352436C (es)
CO (1) CO5150238A1 (es)
CZ (1) CZ297412B6 (es)
DE (2) DE19901921C2 (es)
DK (1) DK1144386T3 (es)
EA (1) EA003065B1 (es)
EE (1) EE04344B1 (es)
ES (1) ES2208265T3 (es)
HK (1) HK1041485B (es)
HR (1) HRP20010514B1 (es)
HU (1) HU227401B1 (es)
IL (2) IL143634A0 (es)
MY (1) MY122755A (es)
NO (1) NO319823B1 (es)
NZ (1) NZ513528A (es)
PE (1) PE20001362A1 (es)
PL (1) PL211829B1 (es)
PT (1) PT1144386E (es)
RS (1) RS50044B (es)
SA (1) SA99200838B1 (es)
SK (1) SK285429B6 (es)
TR (1) TR200102074T2 (es)
TW (1) TWI280241B (es)
UA (1) UA56358C2 (es)
UY (1) UY25980A1 (es)
WO (1) WO2000043370A1 (es)
ZA (1) ZA200104771B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153737A1 (de) * 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
PT1467712E (pt) 2002-01-16 2008-01-09 Boehringer Ingelheim Pharma Comprimido farmacêutico de duas camadas compreendendo telmisartan e hidroclorotiazida
DE10314702A1 (de) * 2003-03-31 2004-10-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von Telmisartan
GB2414019A (en) * 2004-05-11 2005-11-16 Cipla Ltd One-step preparation of telmisartan by condensation and hydrolysis
JP2008503595A (ja) 2004-10-15 2008-02-07 テバ ファーマシューティカル インダストリーズ リミティド テルミサルタンの調製方法
WO2006044754A2 (en) 2004-10-18 2006-04-27 Dr. Reddy's Laboratories Ltd. Process for preparing telmisartan
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
MX346039B (es) 2009-05-20 2017-03-03 Boehringer Ingelheim Vetmedica Gmbh Solucion farmaceutica bebible de telmisartan.
PL2443094T3 (pl) 2009-06-19 2013-08-30 Krka Tovarna Zdravil D D Novo Mesto Sposób wytwarzania telmisartanu
EP2277866A1 (en) 2009-06-22 2011-01-26 Inke, S.A. Process for preparing telmisartan
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
EP2448576A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2632438A1 (en) 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
ITMI20102416A1 (it) * 2010-12-27 2012-06-28 Chemelectiva S R L Intermedio per la preparazione di un principio attivo e processo per la sua preparazione
EP2612658A1 (en) 2012-01-05 2013-07-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
JP6147546B2 (ja) * 2013-04-10 2017-06-14 株式会社トクヤマ 酢酸が低減されたテルミサルタンａ型結晶の製造方法
EP2979691A1 (en) 2014-07-30 2016-02-03 Boehringer Ingelheim International GmbH Oral disintegrating tablet
JP6275596B2 (ja) * 2014-09-03 2018-02-07 株式会社トクヤマ テルミサルタンのアンモニウム塩の製造方法
JP5871294B1 (ja) 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
KR20170001921A (ko) 2015-06-26 2017-01-05 대원제약주식회사 안정성이 개선된 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
KR20170012703A (ko) 2015-07-22 2017-02-03 대원제약주식회사 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
JP6411662B2 (ja) 2016-05-30 2018-10-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 固定容量配合剤
KR102044223B1 (ko) * 2016-09-12 2019-11-13 성균관대학교산학협력단 텔미사르탄을 포함하는 고체 분산체 및 이의 제조방법
CN106749037B (zh) * 2016-12-21 2019-06-21 山东大学 一种无定型的替米沙坦-戊二酸共晶及其制备方法和应用
CN106749036B (zh) * 2016-12-21 2019-06-21 山东大学 一种无定型的替米沙坦-庚二酸共晶及其制备方法和应用
CA3067918A1 (en) 2017-07-07 2019-01-10 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonish for the prevention or treatment of hypertension in cats
CN109851562A (zh) * 2019-01-30 2019-06-07 浙江省食品药品检验研究院 一种替米沙坦晶体及其制备方法
WO2023001880A1 (en) 2021-07-22 2023-01-26 Krka, D. D., Novo Mesto Bilayer tablet comprising telmisartan and indapamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5139114A (en) * 1991-03-18 1992-08-18 Abex Corporation Visible brake block wear indicator

Also Published As

Publication number Publication date
HUP0105148A2 (hu) 2002-07-29
DE19901921A1 (de) 2000-08-03
KR100658959B1 (ko) 2006-12-19
PL349425A1 (en) 2002-07-29
CZ297412B6 (cs) 2006-12-13
ZA200104771B (en) 2002-12-02
HK1041485B (zh) 2004-10-08
UA56358C2 (uk) 2003-05-15
ES2208265T3 (es) 2004-06-16
NO319823B1 (no) 2005-09-19
CN1336920A (zh) 2002-02-20
HRP20010514A2 (en) 2002-08-31
DE19901921C2 (de) 2001-01-04
YU51101A (sh) 2004-05-12
NO20013560L (no) 2001-09-18
DE50004150D1 (de) 2003-11-27
EE04344B1 (et) 2004-08-16
ATE252564T1 (de) 2003-11-15
BR0007584A (pt) 2001-11-06
PE20001362A1 (es) 2000-12-15
MY122755A (en) 2006-05-31
IL143634A0 (en) 2002-04-21
KR20010101552A (ko) 2001-11-14
BG65027B1 (bg) 2006-12-29
RS50044B (sr) 2008-11-28
JP2002535315A (ja) 2002-10-22
BG105654A (en) 2002-01-31
EP1144386B1 (de) 2003-10-22
SK285429B6 (sk) 2007-01-04
EE200100375A (et) 2002-10-15
EP1144386A1 (de) 2001-10-17
CN1144790C (zh) 2004-04-07
PT1144386E (pt) 2004-03-31
NZ513528A (en) 2003-08-29
SA99200838B1 (ar) 2006-03-06
EA003065B1 (ru) 2002-12-26
JP4700813B2 (ja) 2011-06-15
TR200102074T2 (tr) 2001-12-21
SK10202001A3 (sk) 2001-12-03
IL143634A (en) 2006-10-05
HU227401B1 (en) 2011-05-30
HRP20010514B1 (en) 2010-01-31
TWI280241B (en) 2007-05-01
CO5150238A1 (es) 2002-04-29
AU765081B2 (en) 2003-09-11
HUP0105148A3 (en) 2003-01-28
CA2352436A1 (en) 2000-07-27
CZ20012634A3 (cs) 2001-10-17
WO2000043370A1 (de) 2000-07-27
EA200100730A1 (ru) 2002-02-28
NO20013560D0 (no) 2001-07-18
UY25980A1 (es) 2001-08-27
DK1144386T3 (da) 2004-01-12
AU2288100A (en) 2000-08-07
PL211829B1 (pl) 2012-06-29
CA2352436C (en) 2010-03-23
HK1041485A1 (en) 2002-07-12

Similar Documents

Publication Publication Date Title
AR035475A1 (es) Forma b polimorfa del telmisartan, las mezclas de los polimorfos del telmisartan, un procedimiento para la preparacion del telmisartan que contiene la forma b polimorfa, y el uso del telmisartan para preparar un medicamento
HRP20221355T1 (hr) Liofilizirani pripravak citotoksičnih dipeptida
CN106866766A (zh) 一种醋酸甲羟孕酮的制备方法及制备系统
PE20050388A1 (es) Procedimiento para la preparacion de ciclesonida cristalina con un tamano definido de particulas
CN101899081B (zh) 甘草次酸酯类衍生物合成方法以及脱氧甘草次酸酯化合物
JP2012528801A5 (es)
CN104557932A (zh) 一种苝酰亚胺类近红外吸收材料的高效合成方法及其应用
CN104387371A (zh) 2-((2-甲基-3-吲哚基)甲基)苯并咪唑衍生物及其合成
KR101354915B1 (ko) 칼로일-펩타이드 및 이를 이용한 피부 외용제 조성물
CN104188978B (zh) 闭花木酮的o-(四氢吡咯基)乙基衍生物在制备治疗或预防肾纤维化药物中的应用
CN102174123B (zh) 一种水溶性黄酮-壳聚糖衍生物的生产方法
CN103980255A (zh) 一种双苯并咪唑衍生物紫外线吸收剂及其制备方法
CN102718830A (zh) 甘草次酸酯类衍生物合成方法
CN104860835B (zh) 同位素标记左旋肉碱‑d3的合成方法
CN104402964B (zh) 闭花木酮的o-(咪唑基)乙基衍生物、制备方法及其用途
CN102885701A (zh) 吴茱萸碱在制备防紫外线组合物中的应用
Hill et al. Some α-Alkylthio Aliphatic Acids
Soni et al. Absorption spectra of heterocyclic compounds. Some 6-hydroxy [1, 3, 4] thiadiazolo [2, 3-b] benzimidazoles and their quaternary derivatives.
CN103408748B (zh) 一种水溶性紫檀芪衍生物的合成方法
CO6470840A2 (es) Formas farmacéuticas solubles de la n, n´-diaminodifenilsulfona para uso óptimo en el tratamiento de diversas enfermedades
CN106220611A (zh) 2‑(1h‑吲哚‑3‑基)‑1h‑苯并咪唑衍生物的新制备方法
CN104031099B (zh) 一种含双丙叉基的糖化合物脱丙叉的催化方法
Johnson et al. Pyrazinoindole-1, 4-diones. Ring Closure of 2-Indolecarbonyl Derivatives of α-Aminoesters
Marvel et al. Cyclic Dimercaptals and Dimercaptols from Alkylene Dithiols1
Price et al. Some naphthalene analogs of desoxycorticosterone

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FG Grant, registration